ADLAI NORTYE LTD. Share Price Today: Live Updates & Key Insights

ADLAI NORTYE LTD. share price today is $12.04, up -5.45%. The stock opened at $12.64 against the previous close of $13.22, with an intraday high of $12.93 and low of $12.1.

ADLAI NORTYE LTD. Share Price Chart

ADLAI NORTYE LTD.

us-stock
To Invest in {{usstockname}}
us-stock

ADLAI NORTYE LTD. Share Price Performance

$12.04 -0.0545(-5.45%) ANL at 27 Jul 2026 01:58 PM Biotechnology
Lowest Today 12.1
Highest Today 12.93
Today’s Open 12.64
Prev. Close 13.22
52 Week High 17.25
52 Week Low 0.88
Day’s Range: Low 12.1 High 12.93
52-Week Range: Low 0.88 High 17.25
1 day return -
1 Week return +4.07
1 month return +24.87
3 month return -9.09
6 month return +294.32
1 year return +762.06
3 year return -17.16
5 year return -
10 year return -

ADLAI NORTYE LTD. Institutional Holdings

VR Adviser, LLC 4.99

Cormorant Asset Management, LLC 4.50

Squadron Capital Management LLC 1.96

Balyasny Asset Management LLC 1.36

Millennium Management LLC 1.06

Adage Capital Partners Gp LLC 0.84

Casdin Capital, LLC 0.84

SUPERSTRING CAPITAL MANAGEMENT LP 0.64

Woodline Partners LP 0.32

Affinity Asset Advisors, LLC 0.26

UBS Group AG 0.19

Ameriprise Financial Inc 0.19

ADAR1 Capital Management LLC 0.18

T. Rowe Price Associates, Inc. 0.16

Renaissance Technologies Corp 0.10

Tidal Investments LLC. 0.10

Tema Oncology ETF 0.07

CANTOR FITZGERALD, L. P. 0.06

TD Asset Management Inc 0.06

Ikarian Capital, LLC 0.05

Persistent Asset Partners Limited 0.05

Virtus LifeSci Biotech Clinical Trls ETF 0.05

Fidelity Nasdaq Composite Index 0.02

Telescope Biotech Fund A FIL 0.01

ADLAI NORTYE LTD. Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

ADLAI NORTYE LTD. Fundamentals

Market Cap 851.34 M

PB Ratio 82.7603

PE Ratio 0.0

Enterprise Value 871.27 M

Total Assets 34.43 M

Volume 130695

ADLAI NORTYE LTD. Company Financials

Annual Revenue FY23:4995653 5.0M, FY22:0 0.0M, FY21:45726000 45.7M

Annual Profit FY23:2775585 2.8M, FY22:null 0.0M, FY21:45726000 45.7M

Annual Net worth FY23:-104779839 -104.8M, FY22:-58790000 -58.8M, FY21:-56678000 -56.7M

Quarterly Revenue Q1/2026:2500000 2.5M, Q2/2024:745000 0.7M, Q1/2024:745000 0.7M, Q4/2023:2500000 2.5M, Q3/2023:2500000 2.5M

Quarterly Profit Q1/2026:2500000 2.5M, Q2/2024:745000 0.7M, Q1/2024:745000 0.7M, Q4/2023:2500000 2.5M, Q3/2023:2500000 2.5M

Quarterly Net worth Q1/2026:-8596500 -8.6M, Q2/2024:-13806000 -13.8M, Q1/2024:-13806000 -13.8M, Q4/2023:-13226500 -13.2M, Q3/2023:-13226500 -13.2M

About ADLAI NORTYE LTD. & investment objective

Company Information Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.

Organisation Biotechnology

Employees 109

Industry Biotechnology

CEO Mr. Yang Lu EMBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ADLAI NORTYE LTD. FAQs

What is the share price of ADLAI NORTYE LTD. today?

The current share price of ADLAI NORTYE LTD. is $12.04.

Can I buy ADLAI NORTYE LTD. shares in India?

Yes, Indian investors can buy ADLAI NORTYE LTD. shares by opening an international trading and demat account with Motilal Oswal.

How to buy ADLAI NORTYE LTD. shares in India?

You can easily invest in ADLAI NORTYE LTD. shares from India by:

Can I buy fractional shares of ADLAI NORTYE LTD.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ADLAI NORTYE LTD.?

ADLAI NORTYE LTD. has a market cap of $851.34 M.

In which sector does ADLAI NORTYE LTD. belong?

ADLAI NORTYE LTD. operates in the Biotechnology sector.

What documents are required to invest in ADLAI NORTYE LTD. stocks?

To invest, you typically need:

What is the PE and PB ratio of ADLAI NORTYE LTD.?

The PE ratio of ADLAI NORTYE LTD. is N/A and the PB ratio is 82.76.